What does this research mean for the field?

Inclisiran significantly reduces LDL-C by 49.3 mg/dL and PWV from 10.9 to 9.8 m/s after 1 year in patients on lipid-lowering therapy. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

February 8, 2026

Pleiotropic effects of inclisiran on arterial structural and functional parameters

Key Result

Inclisiran lowered LDL-C by 52% and significantly reduced carotid-femoral PWV from 10.9 to 9.8 m/s over 1 year in dyslipidemic patients.

Key Points

This study evaluates the effects of inclisiran on arterial structural and functional properties in patients using this therapy for dyslipidemia.
Prospective longitudinal study with patients starting inclisiran therapy.
Administered inclisiran injections at baseline, 3 months, and every 6 months thereafter.
Measured carotid-femoral pulse wave velocity, intima media thickness, and flow mediated dilation at baseline, 6 months, and 1 year.
Significant reduction of LDL-C from 102.7±49.6 mg/dL to 49.3±16.4 mg/dL (p<0.001).
Blood pressure decreased from 140.6±13.3/79.1±6.1 mmHg to 126.9±10.1/71.2±6.5 mmHg (p<0.001).
Pulse wave velocity significantly reduced from 10.9±2.0 to 9.8±1.4 m/s (p<0.001).
No significant changes in intima media thickness or flow mediated dilation.

Structured PICO

Does inclisiran improve arterial structural and functional parameters in patients with dyslipidemia?

Population

15 patients with dyslipidemia starting inclisiran therapy, mean age 69±7.1 years, 72.7% men, 90.9% in secondary prevention (acute or chronic coronary syndrome).

Intervention

Inclisiran injections administered at T0, after 3 months and then every 6 months for 1 year.

Outcome

Changes in Carotid-femoral Pulse Wave Velocity (PWV), carotid Intima Media Thickness (IMT) and brachial Flow Mediated Dilation (FMD) at 1 year.surrogate

Inclisiran therapy over 1 year significantly reduces carotid-femoral pulse wave velocity, suggesting potential benefits on arterial stiffness beyond LDL-C lowering.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Background and objectives Inclisiran is the latest PCSK9 inhibitor available for reducing LDL-cholesterol. Its effects on arterial structural and functional properties are not yet known. The purpose of our study is to longitudinally evaluate these properties in patients starting therapy with this new drug for dyslipidemia. Methods Prospective longitudinal study enrolling all patients who started Inclisiran therapy at our hospital. Inclisiran injections were administered at T0, after 3 months and then every 6 months. Carotid-femoral Pulse Wave Velocity (PWV), carotid Intima Media Thickness (IMT) and brachial Flow Mediated Dilation (FMD) were evaluated before the first injection, after 6 months (T1) and after 1 year (T2). Data from 15 patients at 1 year were analyzed. Results The mean age was 69±7.1 years, 72.7% of the subjects were men and the basal LDL-C was 102.7±49.6 mg/dL, while BP was 140.6±13.3/79.1±6.1 mmHg. 90.9% of patients were in secondary prevention (acute or chronic coronary syndrome). 86.4% were on high-intensity statin therapy and 81.8% on ezetimibe. At the 1 year’s evaluation, a significant reduction of LDL-C (49.3±16.4 mg/dL, p0.001) and BP (126.9±10.1/71.2±6.5 mmHg, p0.001) was observed. Among the arterial biomarkers, only PWV showed a significant reduction (from 10.9±2.0 to 9.8±1.4 m/s, p0.001) while the changes in IMT (from 705.9±151.3 to 696.0±202.1 μm, p=0.333) and FDM (from 7.5±8.9 a 6.9±8.0%, p=0.449) were not statistically significant. Conclusions Inclisiran has been confirmed as an excellent LDL-C lowering drug that also significantly reduces PWV. Studies with a larger number of patients are needed to confirm our findings.

Mark Helpful

Bookmark

Relay